Biohaven's Ratty Setback; How Xenon Benefits

Biohaven Ltd. (BHVN) shares fell after the FDA placed a partial clinical hold on its BHV-7000 epilepsy program, raising concerns about safety and development timelines. The company has a $400M licensing deal but faces high debt and potential cash burn. Investors are reassessing execution risks.

Biohaven Ltd. (BHVN) shares fell after the FDA placed a partial clinical hold on its epilepsy drug candidate BHV-7000, introducing regulatory uncertainty and delaying progress. Investors also expressed concerns over the company's valuation and cash burn, intensifying selling pressure. Despite the setback, Biohaven has a $400 million funding deal and partnerships to extend its cash runway, but its stretched balance sheet and high cash burn remain risks.

Biohaven Ltd. (BHVN) shares surged after reporting positive Phase 3 trial results for troriluzole in treating Spinocerebellar Ataxia, meeting its main goal. The data may lead to an FDA application, potentially transforming the company into a commercial entity with a new revenue stream. Investors are optimistic but should monitor debt, cash burn, and regulatory risks.

Biohaven Ltd. (BHVN) shares rose 13% after licensing its epilepsy drug program to SK Biopharmaceuticals for up to $795M plus royalties. The deal includes $400M upfront, with Biohaven retaining royalties. SK aims to launch the drug in the U.S. by 2029. Biohaven plans to focus on other pipeline drugs, including obesity and immunology treatments. Raymond James cut its price target to $30 but maintains a 'Strong Buy' rating.

Biohaven Ltd. (BHVN) faces a securities investigation after the FDA placed a partial clinical hold on its epilepsy treatment BHV-7000, causing shares to drop 15% on Sept. 10. Levi & Korsinsky LLP is probing potential securities law violations. The FDA's action is based on insufficient data on a metabolite observed in rodent tests. Biohaven maintains that over 1,200 participants have safely received BHV-7000, and topline results from a pivotal study remain on track for 2026.

Biohaven's epilepsy drug trials paused by FDA due to rodent study findings. New enrollments halted, but current patients continue dosing. Biohaven shares fell over 10% post-announcement. The company expects new animal data soon and maintains the drug has been safe in over 1,200 participants. Top-line results from one study are still expected in 2H 2026.